As part of this collaboration, EuroAPI will supply its client with a key veterinary product. The total contract value is expected to range between €130 and 150 million, over the 2025-2029 period. 

“The conclusion of this major contract secures the long-term supply of a complex chemical molecule, crucial for veterinary use. This is a true recognition of EuroAPI’s know-how and of the reliability of the premium service we offer to our customers,” commented Ludwig de Mot, Chief Executive Officer of EuroAPI. “This agreement will be a key driver of our FOCUS-27 project sales trajectory.”

EuroAPI has expertise within the animal health sector with many customers and products in its portfolio such as hormones, prostaglandins and complex synthesis molecules. The value of the global animal health market has been estimated by Health for Animals at $41.8 billion (€38.6 billion) in 2023 and is expected to reach $56.8 billion (€52.5 billion) by 2030, at a CAGR of 4.5%.